Journal: bioRxiv

Article Title: Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray

doi: 10.1101/2020.03.24.006544

Figure Lengend Snippet: Non-coronavirus respiratory virus antigens on microarray.

Article Snippet: RSV , A , rsb1734 , G , , HEK293 , Sino Biological , N-(AA66-297)-His-C , 11070-V08H.

Techniques: Microarray, Expressing, Construct

Journal: bioRxiv

Article Title: Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray

doi: 10.1101/2020.03.24.006544

Figure Lengend Snippet: Coronavirus antigens on microarray.

Article Snippet: RSV , A , rsb1734 , G , , HEK293 , Sino Biological , N-(AA66-297)-His-C , 11070-V08H.

Techniques: Microarray, Expressing, Construct

Journal: Frontiers in Molecular Biosciences

Article Title: Interactions of heparin with key glycoproteins of human respiratory syncytial virus

doi: 10.3389/fmolb.2023.1151174

Figure Lengend Snippet: SPR sensorgrams of RSV-G protein and RSV-F protein binding with heparin. (A) SPR sensorgrams of RSV-G protein binding with heparin. Concentrations of RSV-G protein (from top to bottom) are 500, 250, 125, 62.5 and 31.3 nM, respectively. (B) SPR sensorgrams of RSV-F protein binding with heparin. Concentrations of RSV-F protein (from top to bottom) are 80, 40, 20, 10, and 5 nM, respectively.

Article Snippet: RSV-G protein (Cat: 11070-V08H2), RSV-F protein (Cat: 40628-V08B) were purchased from Sino Biological Inc.

Techniques: Protein Binding

Journal: Frontiers in Molecular Biosciences

Article Title: Interactions of heparin with key glycoproteins of human respiratory syncytial virus

doi: 10.3389/fmolb.2023.1151174

Figure Lengend Snippet: RSV-G protein–heparin interaction inhibited by heparin oligosaccharides or desulfated heparins using solution competition. (A) SPR sensorgrams of RSV-G protein–heparin interaction competing with different heparin oligosaccharides. Concentration of RSV-G protein is 250 nM mixed with 1,000 nM of different heparin oligosaccharides. (B) Bar graphs (based on triplicate experiments with standard deviation) of normalized RSV-G protein binding to surface-immobilized heparin by competing with different heparin oligosaccharides. (C) SPR sensorgrams of RSV-G protein–heparin interaction competing with different desulfated heparins. Concentration of RSV-G protein is 250 nM mixed with 1,000 nM of different desulfated heparins. (D) Bar graphs (based on triplicate experiments with standard deviation) of normalized RSV-G protein binding to surface-immobilized heparin by competing with different desulfated heparins. Statistical analysis was performed using unpaired two-tailed t -test (ns: p > 0.05 compared to the control, *: p ≤ 0.05 compared to the control, **: p ≤ 0.01 compared to the control, ***: p ≤ 0.001 compared to the control).

Article Snippet: RSV-G protein (Cat: 11070-V08H2), RSV-F protein (Cat: 40628-V08B) were purchased from Sino Biological Inc.

Techniques: Concentration Assay, Standard Deviation, Protein Binding, Two Tailed Test

Journal: Frontiers in Molecular Biosciences

Article Title: Interactions of heparin with key glycoproteins of human respiratory syncytial virus

doi: 10.3389/fmolb.2023.1151174

Figure Lengend Snippet: Solution competition between heparin and PPS or MPS. (A) Structure of PPS and MPS. (B) SPR sensorgrams of RSV-G protein–heparin interaction competing with PPS or MPS. Concentration of RSV-G protein is 250 nM mixed with 1,000 nM of PPS or MPS. (C) Bar graphs (based on triplicate experiments with standard deviation) of normalized RSV-G protein binding to surface-immobilized heparin by competing with PPS or MPS. (D) SPR sensorgrams of RSV-F protein–heparin interaction competing with PPS or MPS. Concentration of RSV-F protein is 40 nM mixed with 1,000 nM of PPS or MPS. (E) Bar graphs (based on triplicate experiments with standard deviation) of normalized RSV-F protein binding to surface-immobilized heparin by competing with PPS or MPS. Statistical analysis was performed using unpaired two-tailed t -test (***: p ≤ 0.001 compared to the control, #: p ≤ 0.05 compared to heparin, ##: p ≤ 0.01 compared to heparin).

Article Snippet: RSV-G protein (Cat: 11070-V08H2), RSV-F protein (Cat: 40628-V08B) were purchased from Sino Biological Inc.

Techniques: Concentration Assay, Standard Deviation, Protein Binding, Two Tailed Test

Journal: MedComm

Article Title: Combining Intramuscular and Intranasal Immunization With the MF59‐Adjuvanted Respiratory Syncytial Virus Pre‐Fusion Protein Subunit Vaccine Induces Potent Humoral and Cellular Immune Responses in Mice

doi: 10.1002/mco2.70301

Figure Lengend Snippet: IM immunization with MF59/preF vaccine induced systemic humoral and B‐cell immune responses. (A) The schematic representation of the mouse immunization and sample collection protocol. Mice were immunized intramuscularly with PBS, MF59, preF, MF59/preF‐low, or MF59/preF‐high on Days 0, 21, and 42. Sera were collected on Days 14, 35, and 56, and BALF, spleen, lung, and ILN were harvested on day 72. (B) Endpoint titers of anti‐preF/postF IgG in sera from mice intramuscularly immunized with adjuvanted preF on Days 14, 35, and 56. (C) Titers of virus neutralizing antibody (VNA) against RSV A2 and RSV B in sera collected on Day 56. (D) Endpoint titers of anti‐preF/postF IgG and IgA in BALF collected on Day 72. (E–G) The representative images and quantitative analysis of preF‐specific IgG + ASCs in bone marrow (E), spleen (F), and lung (G). Data are presented as geometric mean values ± SD in B–D. The middle line indicates the median while the whisker shows the data range in E–G. n = 6 mice per group. p values were conducted by One‐way ANOVA analysis followed by Tukey's multiple comparisons test in B, and D–G. **** p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05; ns, not significant.

Article Snippet: Briefly, 96‐well ELISA plates (NUNC‐MaxiSorp, Thermo Fisher Scientific) were coated overnight at 4°C with either 1 μg/mL of RSV preF or postF protein (Sino Biological, 11049‐V49H5‐B).

Techniques: Virus, Whisker Assay

Journal: MedComm

Article Title: Combining Intramuscular and Intranasal Immunization With the MF59‐Adjuvanted Respiratory Syncytial Virus Pre‐Fusion Protein Subunit Vaccine Induces Potent Humoral and Cellular Immune Responses in Mice

doi: 10.1002/mco2.70301

Figure Lengend Snippet: IN immunization with MF59/preF vaccine induced local humoral and B‐cell immune responses. (A) The schematic representation of the mouse immunization and sample collection protocol. Mice were immunized intranasally with PBS, MF59, preF, MF59/preF‐low, or MF59/preF‐high on Days 0, 21, and 42. Sera were collected on Days 14, 35, and 56, and BALF, spleen, lung, and mLN were harvested on Day 72. (B) Endpoint titers of anti‐preF/postF IgG in sera from mice intranasally immunized with adjuvanted preF on Days 14, 35, and 56. (C) Titers of virus neutralizing antibody (VNA) against RSV A2 and RSV B in sera collected on Day 56. (D) Endpoint titers of anti‐preF/postF IgG and IgA in BALF collected on Day 72. (E–J) The representative images and quantitative analysis of preF‐specific IgG + (left) and IgA + (right) ASCs in bone marrow (E, H), spleen (F, I), and lung (G, J). Data are presented as geometric mean values ± SD in B–D. The middle line indicates the median while the whisker shows the data range in E–J. n = 6 mice per group. p values were conducted by One‐way ANOVA analysis followed by Tukey's multiple comparisons test in B, and D–J. **** p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05; ns, not significant.

Article Snippet: Briefly, 96‐well ELISA plates (NUNC‐MaxiSorp, Thermo Fisher Scientific) were coated overnight at 4°C with either 1 μg/mL of RSV preF or postF protein (Sino Biological, 11049‐V49H5‐B).

Techniques: Virus, Whisker Assay

Journal: MedComm

Article Title: Combining Intramuscular and Intranasal Immunization With the MF59‐Adjuvanted Respiratory Syncytial Virus Pre‐Fusion Protein Subunit Vaccine Induces Potent Humoral and Cellular Immune Responses in Mice

doi: 10.1002/mco2.70301

Figure Lengend Snippet: Combination of IM and IN immunization using MF59/preF vaccine elicited both local and systemic humoral and B‐cell immune responses. (A–B) The schematic representation of the mouse immunization and sample collection protocol. BALB/c mice received two intramuscular doses of the MF59/preF vaccine followed by a single intranasal dose (IM‐IM‐IN), or one intramuscular dose followed by two intranasal doses (IM‐IN‐IN). Sera were collected on Days 14, 35, and 56, and BALF, spleen, lung, and mLN were harvested on Day 72. (C) Endpoint titers of anti‐preF/postF IgG in sera on Day 56. (D) Titers of virus neutralizing antibody (VNA) against RSV A2 and RSV B in sera collected on Day 56. (E) Endpoint titers of anti‐preF/postF IgG and IgA in BALF collected on Day 72. (F‐K) The representative images and quantitative analysis of preF‐specific IgG + (left) and IgA + (right) ASCs in bone marrow (F, I), spleen (G, J), and lung (H, K). Data are presented as geometric mean values ± SD in C–E. The middle line indicates the median while the whisker shows the data range in F–K. n = 6 mice per group. p values were conducted by One‐way ANOVA analysis followed by Tukey's multiple comparisons test in C–K. **** p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05; ns, not significant.

Article Snippet: Briefly, 96‐well ELISA plates (NUNC‐MaxiSorp, Thermo Fisher Scientific) were coated overnight at 4°C with either 1 μg/mL of RSV preF or postF protein (Sino Biological, 11049‐V49H5‐B).

Techniques: Virus, Whisker Assay